CLINICAL TRIALS PROFILE FOR SEROMYCIN
✉ Email this page to a colleague
All Clinical Trials for Seromycin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00182000 ↗ | Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy | Completed | Hartford Hospital | Phase 3 | 2003-11-01 | This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD). |
NCT00182000 ↗ | Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy | Completed | Massachusetts General Hospital | Phase 3 | 2003-11-01 | This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD). |
NCT00198120 ↗ | Safety and Effectiveness of D-Cycloserine in Children With Autism | Completed | Indiana University School of Medicine | Phase 3 | 2004-02-01 | This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children. |
NCT00198120 ↗ | Safety and Effectiveness of D-Cycloserine in Children With Autism | Completed | National Alliance for Research on Schizophrenia and Depression | Phase 3 | 2004-02-01 | This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children. |
NCT00198120 ↗ | Safety and Effectiveness of D-Cycloserine in Children With Autism | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2004-02-01 | This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children. |
NCT00198120 ↗ | Safety and Effectiveness of D-Cycloserine in Children With Autism | Completed | Indiana University | Phase 3 | 2004-02-01 | This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children. |
NCT00408031 ↗ | D-cycloserine for Major Depressive Disorder | Completed | National Alliance for Research on Schizophrenia and Depression | Phase 2 | 2007-01-01 | For many depression patients treatment changes are required, including switching to another antidepressant and addition of a second antidepressant or a non-antidepressant agent ("augmentation"). The need to modify treatment is usually necessary because of partial or no response to first-line monotherapy or the failure to achieve remission although treatment response (improvement) has been obtained. These caveats of presently available antidepressant drugs highlight the need for innovative pharmacological treatment strategies. Recent data suggest that N-methyl-D-aspartate receptor (NMDAR) antagonists and partial agonists at the NMDAR-associated glycine binding site may represent a novel type of antidepressant medications. These types of compounds protect vulnerable neurons against a variety of insults, including stress-induced damage, and may serve to enhance and maintain normal synaptic connectivity. In animal models, these compounds mimic the effects of clinically effective antidepressants. Furthermore, down-regulation of the glycine site of the NMDAR was found to be a common feature of currently used antidepressant medications. D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated glycine site. Beneficial antidepressant effects have been reported with 500-1000 mg/day DCS regimens in depressed tuberculosis patients and recent preliminary findings suggest that DCS may also be beneficial in the treatment of major depressive disorder. The antidepressant effects of DCS seem to reflect consequences of its capacity to reduce NMDAR receptor function. In the present project, it is proposed to assess, using a random assignment, parallel-group, double blind, placebo controlled design, the effects of a NMDAR -antagonist DCS dose regimen, 250 --> 1000 mg/day for 6 wks, as adjuvant pharmacotherapy for treatment-resistant major depressive disorder patients. The study methodology includes the assessment of DCS effects upon symptoms profile, neurocognitive tests performance, amino acids serum levels, and brain electrophysiology parameters associated with the prepulse inhibition-startle response paradigm. It is hypothesized that significant beneficial DCS treatment effects will be registered. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Seromycin
Condition Name
Clinical Trial Locations for Seromycin
Trials by Country
Clinical Trial Progress for Seromycin
Clinical Trial Phase
Clinical Trial Sponsors for Seromycin
Sponsor Name